Clinical Trials in Tennessee

Showing 12961-12980 of 17,345 trials

An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis

NCT01462318

The primary objective of the study is to assess the immunogenicity of Daclizumab High Yield Process (DAC HYP) 150 mg administered every 4 weeks by subcutaneous (SC) injection using the pre-filled syringe (PFS) in participants with relapsing-remitting multiple sclerosis (RRMS). The secondary objectives of this study are to characterize the pharmacokinetics (PK) of DAC HYP following single and multiple doses of DAC HYP administered by the PFS in a subset of participants with RRMS and to evaluate the effect of DAC HYP on the PK of probe drugs for cytochrome P450 (CYP) isoenzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A).

Relapsing-Remitting Multiple Sclerosis

Biogen133 participantsStarted Nov 2011

Centennial, Colorado, United States • Washington D.C., District of Columbia, United States • Lake Barrington, Illinois, United States +16 more locations

WITHDRAWNNA29 miles

Intracoronary Bradykinin Mediated t-PA Release in Heart Transplant Recipients

NCT00780377

Heart transplant recipients do not have nerves to their hearts. This protocol tests the hypothesis that bradykinin mediated t-PA release in the coronary arteries will be reduced in heart transplant recipients compared to healthy subjects. This study will compare heart transplant recipients to healthy controls who are undergoing cardiac cath for standard of care purposes (separate protocol) and compare the coronary arteries to the forearm in transplant recipients (separate protocol) and healthy controls (separate protocol).

Heart Transplantation

Vanderbilt UniversityStarted Oct 2008

Nashville, Tennessee, United States

An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis

Intracoronary Bradykinin Mediated t-PA Release in Heart Transplant Recipients

Find Trials by Condition in Tennessee

Safety and Efficacy of Turoctocog Alfa in Haemophilia A Subjects

Biomarkers in Patients With Head and Neck Cancer and in Healthy Volunteers

SinuSurf vs. Saline Solution in Normal Subjects

Micro-Layer Ablation of Barrett's Metaplasia- A Two-Phase, Multi-Center Trial - Extension of Follow-up to 5 Years

Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes

Individualized Therapy For Asthma in Toddlers

Vitamin D/Calcium Polyp Prevention Study

Pyridoxine and Topical Urea/Lactic Acid-Based Cream in Preventing Hand-Foot Syndrome in Patients Receiving Capecitabine for Breast Cancer or Other Cancer

Asthma Phenotypes in the Inner City

A Study of NewGam, Human Immunoglobulin 10%, in Patients With Primary Immunodeficiency Diseases

Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia

Use of Ultrase® MT12 in Young Cystic Fibrosis Children (CF)

Stepped Enhancement of PTSD Services Using Primary Care (STEPS UP): A Randomized Effectiveness Trial

Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA)

Pazopanib in Treating Patients With Recurrent Glioblastoma

The Effect of Diflunisal on Familial Amyloidosis

Switching Drug Therapy for the Prevention of Blood Clot Formation From Enoxaparin to Rivaroxaban After Orthopedic Surgery for Either Total Hip or Total Knee Replacement

Phase I Study of CBP501 and Cisplatin in Patients With Advanced Refractory Solid Tumors